Table 2: The Efficacy of Ivermectin among the Respondents in Idogun Community.
Age Group (Year) | Number Infected before treatment (Prev.) | Number Infected after 6months (Prev.) | Efficacy (%) ± SE | Number Infected after 12 months (Prev.) | Efficacy (%) ± SE | Df | F-value | P-Value |
10-20 | 4 (16.7) | 3 (12.5) | 25.1d ± 0.37 | 1 (4.2) | 74.9d ± 1.65 | 6 | 18.000 | 0.000 |
21-30 | 8 (20) | 6 (15) | 25d ± 0.54 | 1 (2.5) | 87.5e ± 1.89 | |||
31-40 | 6 (20) | 4 (13.3) | 33.5e ±1.31 | 2 (6.7) | 66.5d ±1.37 | |||
41-50 | 28 (28) | 25 (25) | 10.7c ± 0.39 | 16 (16) | 42.9c ± 1.52 | |||
51-60 | 34 (43.6) | 32 (41.0) | 6.0b ± 0.37 | 26 (33.3) | 23.6b ± 1.71 | |||
61-70 | 16 (24.4) | 15 (22.7) | 7b ± 0.36 | 12 (18.2) | 25.4b ± 1.32 | |||
71-80 | 12 (33.3) | 12 (33.3) | 0a ± 0.0 | 10 (27.8) | 16.5a ± 1.27 | |||
Total | 108 (28.1) | 97 (25.3) | 10.0 | 68 (17.7) | 37.0 |
Note: Figures with the same superscript are not significantly different while figures with different superscripts are significantly different across the columns.
Letter a-e are used to separate the efficacies across the age groups after significant difference was been established by One-Way ANOVA at P < 0.05.